157 related articles for article (PubMed ID: 26370966)
1. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
[TBL] [Abstract][Full Text] [Related]
2. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments.
Calvanese L; Sandomenico A; Caporale A; Focà A; Focà G; D'Auria G; Falcigno L; Ruvo M
J Pept Sci; 2015 Apr; 21(4):283-93. PubMed ID: 25588905
[TBL] [Abstract][Full Text] [Related]
3. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
4. Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach.
Calvanese L; Marasco D; Doti N; Saporito A; D'Auria G; Paolillo L; Ruvo M; Falcigno L
Biopolymers; 2010 Nov; 93(11):1011-21. PubMed ID: 20629020
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the interaction of a monoclonal antibody and Nodal peptides by STD-NMR spectroscopy.
Calvanese L; Focà A; Sandomenico A; Focà G; Caporale A; Doti N; Iaccarino E; Leonardi A; D'Auria G; Ruvo M; Falcigno L
Bioorg Med Chem; 2017 Dec; 25(24):6589-6596. PubMed ID: 29113739
[TBL] [Abstract][Full Text] [Related]
6. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
7. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells.
Parisi S; D'Andrea D; Lago CT; Adamson ED; Persico MG; Minchiotti G
J Cell Biol; 2003 Oct; 163(2):303-14. PubMed ID: 14581455
[TBL] [Abstract][Full Text] [Related]
8. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
9. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
10. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
11. A GPI processing phospholipase A2, PGAP6, modulates Nodal signaling in embryos by shedding CRIPTO.
Lee GH; Fujita M; Takaoka K; Murakami Y; Fujihara Y; Kanzawa N; Murakami KI; Kajikawa E; Takada Y; Saito K; Ikawa M; Hamada H; Maeda Y; Kinoshita T
J Cell Biol; 2016 Dec; 215(5):705-718. PubMed ID: 27881714
[TBL] [Abstract][Full Text] [Related]
12. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms.
Yeo C; Whitman M
Mol Cell; 2001 May; 7(5):949-57. PubMed ID: 11389842
[TBL] [Abstract][Full Text] [Related]
13. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.
Harms PW; Chang C
Genes Dev; 2003 Nov; 17(21):2624-9. PubMed ID: 14563676
[TBL] [Abstract][Full Text] [Related]
14. TGF-β superfamily member Nodal stimulates human β-cell proliferation while maintaining cellular viability.
Boerner BP; George NM; Targy NM; Sarvetnick NE
Endocrinology; 2013 Nov; 154(11):4099-112. PubMed ID: 23970788
[TBL] [Abstract][Full Text] [Related]
15. Cripto stabilizes GRP78 on the cell membrane.
Kouznetsova VL; Hu H; Teigen K; Zanetti M; Tsigelny IF
Protein Sci; 2018 Mar; 27(3):653-661. PubMed ID: 29226519
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity.
Iaccarino E; Calvanese L; Untiveros G; Falcigno L; D'Auria G; Latino D; Sivaccumar JP; Strizzi L; Ruvo M; Sandomenico A
Biochem J; 2020 Apr; 477(8):1391-1407. PubMed ID: 32215602
[TBL] [Abstract][Full Text] [Related]
17. The threonine that carries fucose, but not fucose, is required for Cripto to facilitate Nodal signaling.
Shi S; Ge C; Luo Y; Hou X; Haltiwanger RS; Stanley P
J Biol Chem; 2007 Jul; 282(28):20133-41. PubMed ID: 17504756
[TBL] [Abstract][Full Text] [Related]
18. Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis.
Kenney NJ; Adkins HB; Sanicola M
J Mammary Gland Biol Neoplasia; 2004 Apr; 9(2):133-44. PubMed ID: 15300009
[TBL] [Abstract][Full Text] [Related]
19. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
20. Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
Sandomenico A; Selis F; Sivaccumar JP; Olimpieri P; Iaccarino E; Cicatiello V; Cantile M; Sanna R; Leonardi A; De Falco S; Ruvo M
Biochem Biophys Res Commun; 2024 Jan; 694():149417. PubMed ID: 38150919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
